# Perrigo Company plc (PRGO) Investor Outlook: A High Dividend Yield Amidst a Challenging Valuation Landscape

- Link: https://www.directorstalkinterviews.com/perrigo-company-plc-prgo-investor-outlook-a-high-dividend-yield-amidst-a-challenging-valuation-landscape/4121241301
- Published: 2026-02-24T11:18:49+00:00
- Author: Madison Wilson

Perrigo Company plc (NYSE: PRGO), a prominent player in the healthcare sector, emerges
as a key provider of over-the-counter health and wellness solutions across the globe.
With a market capitalization of $2 billion, Perrigo is headquartered in Dublin, 
Ireland, and operates through its Consumer Self-Care Americas and Consumer Self-
Care International segments, offering a diverse range of products from upper respiratory
solutions to women’s health products.

Currently trading at $14.55, Perrigo’s stock is on the lower end of its 52-week 
range of $12.26 to $29.47. The stock’s price change of -0.42 (-0.03%) indicates 
a period of stabilization following what appears to be a significant downward trend,
considering its 200-day moving average rests at $20.65.

A standout feature for investors is the company’s dividend yield of 7.97%, a rare
find in the healthcare industry. However, the payout ratio of 10,950% raises red
flags about the [sustainability](https://www.directorstalkinterviews.com/sustainability-green-stocks-news)
of such dividends, suggesting that the company may be leveraging debt or other financial
mechanisms to maintain these payouts.

Valuation metrics paint a complex picture for Perrigo. The absence of a trailing
P/E ratio and the presence of a forward P/E of 5.50 indicate potential future earnings
growth, yet also underscore current earnings challenges. The company’s revenue growth
has contracted by 4.10%, and a negative EPS of -0.21, alongside a return on equity
of -0.65%, reflects ongoing profitability issues.

Despite these challenges, analysts paint an optimistic future, with a consensus 
target price ranging from $18.00 to $28.00, and an average target of $21.00. This
indicates a potential upside of 44.33% from current levels, making Perrigo an attractive
consideration for risk-tolerant investors willing to bet on a turnaround. The analyst
ratings include 2 buy and 3 hold recommendations, with no sell ratings, suggesting
a cautious yet hopeful outlook.

From a technical perspective, the stock’s RSI of 59.73 suggests it is neither overbought
nor oversold, offering a neutral stance for momentum traders. Furthermore, the MACD
indicator at 0.08, above the signal line at 0.04, might hint at a potential short-
term bullish trend.

Perrigo’s strategic focus on self-care products, bolstered by well-known brands 
such as Compeed, Mederma, and Nasonex, provides a robust foundation. The company’s
expansive distribution network, spanning retail drug stores, supermarkets, and e-
commerce platforms, positions it well to capture market share despite current financial
hurdles.

Investors intrigued by high dividend yields may find Perrigo’s current valuation
an enticing entry point, albeit with the understanding of the risks associated with
its financial health metrics. As the company navigates through its earnings challenges,
its ability to sustain dividends and improve profitability will be key indicators
of future stock performance.

Share on: